- Last Ratings Update:06/30/2014
- Price as of 06/30/2014 :$257.03
- Net Assets:$5,251 Million
- Peer Rank:16 of 28
- Investment Rating:B+
We rate iShares Nasdaq Biotechnology at B+. This overall rating indicates it is among the top 10% of all closed end funds in its peer group. Positive factors that influence this rating include a well above average total return, low price volatility, low expense structure and long term portfolio management tenure. The fund invests approximately 100% of its assets in stocks and may be considered for investors seeking a Sector - Health/Biotechnology strategy.
POSITIVES AND RISKS
Total return ranks very high in comparison with peers over the last three years. The iShares Nasdaq Biotechnology has returned an annual rate of 7.49% since inception. More recently, the fund has generated a total return of 31.15% in the last five years, 34.70% in the last three years, and 46.21% in the last year. How does that compare to other equity funds? In the last five years, it has outperformed 97% of them. It has also outpaced 99% of its competitors on a three year basis and 96% of them over the last year for the period ending 6/30/2014. On a year to date basis, IBB has returned 17.33%.
Downside risk has been below average. IBB has a draw down risk of -12.92%, which is the largest price decline experienced over the last three years. This fund has a three year standard deviation of 18.8%. This fund has experienced a high level of volatility in its monthly performance over the last 36 months. As of 6/30/2014, the fund was trading at a price of $257.03, which is 1.1% below its 52-week high of $259.87 and 8.8% above its 52-week low of $236.25.
Low expense ratio helps performance. On total assets of $5.25 billion, IBB maintains a low expense ratio compared to its Sector - Health/Biotechnology peers of just 0.48% to cover all operating costs. Brokerage costs for the fund to buy and sell shares are not included in the expense ratio. As IBB is an exchange traded fund, it has no front end or back end load.
The iShares Nasdaq Biotechnology is managed by Diane Hsiung at BlackRock Fund Advisors. This fund is one of 301 BlackRock Fund Advisors exchange-traded funds launched since 3/12/1996 that we track.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV
Latest Stock Upgrades/Downgrades